Business Context and Reporting Period
Coherus BioSciences, Inc. filed this Form 8-K on March 6, 2015, reporting a corporate event related to a prior merger agreement. The filing details the satisfaction of a contingent earn-out obligation to former stockholders of InteKrin Therapeutics Inc.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantifiable financial item disclosed is the issuance of equity securities.
- Equity Issuance: 358,384 shares of common stock (par value $0.0001 per share).
- Recipient: Former stockholders of InteKrin Therapeutics Inc.
Material Changes
The material change reported is the triggering of a milestone payment under the Merger Agreement dated January 8, 2014. The milestone was defined as the first dosing of a patient with the drug candidate INT-131, which occurred on March 6, 2015. Consequently, the earn-out payment became enforceable on that date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general risks. The document strictly addresses the execution of the contractual obligation regarding the unregistered sale of equity securities pursuant to the Merger Agreement.
Investor Verification Checklist
- Verify the exact number of shares issued (358,384) and the date of issuance (March 6, 2015).
- Confirm the terms of the Merger Agreement dated January 8, 2014, regarding the INT-131 milestone.
- Review the impact of this equity issuance on total outstanding shares and potential dilution.
- Check subsequent filings for any cash-based earn-out components not detailed in this specific 8-K.